Clinical Report: Targeting MAGE-A4 and MAGE-A8 with TCR-based Bispecific T Cell Engagers
Overview
This report presents findings from a Phase 1 study evaluating IMA401, a TCR-based bispecific T cell engager targeting MAGE-A4 and MAGE-A8 in patients with advanced solid tumors.
Background
Bispecific T cell engagers (TCEs) have shown success in hematologic malignancies but face challenges in solid tumors, including low target specificity and rapid clearance. IMA401, a next-generation TCR-based TCE, aims to overcome these limitations by targeting intracellular antigens presented on HLA class I molecules, specifically MAGE-A4 and MAGE-A8.
Data Highlights
No numerical data available in the provided material.
Key Findings
IMA401 targets an HLA-A*02:01-presented peptide derived from MAGE-A4 and MAGE-A8.
The selected target peptide shows at least five-fold higher presentation levels on tumor cells compared to a commonly used MAGE-A4-derived epitope.
MAGE-A4/8 gene expression is prevalent in solid tumors, particularly in squamous cell NSCLC (65%) and HNSCC (45%).
Initial antitumor activity was observed in heavily pretreated patients, with manageable adverse events including low-grade cytokine release syndrome.
IMA401 combines a high-affinity TCR domain with a low-affinity T-cell-recruiting domain for enhanced T cell activation.
Clinical Implications
The findings suggest that IMA401 may provide a new therapeutic option for patients with advanced solid tumors expressing MAGE-A4 and MAGE-A8. Ongoing development and further studies will help clarify its role in the treatment landscape.
Conclusion
The Phase 1 study of IMA401 reports initial findings on its use as a TCR-based bispecific T cell engager for targeting MAGE-A4 and MAGE-A8 in advanced solid tumors.
by Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith S. Hecker, Max-Felix Häring, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Olga Veremchuk, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
